<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117844">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02139969</url>
  </required_header>
  <id_info>
    <org_study_id>PE1401</org_study_id>
    <nct_id>NCT02139969</nct_id>
  </id_info>
  <brief_title>GreenLight XPS Laser System Retrospective Chart Review</brief_title>
  <official_title>GreenLight XPS Laser System for the Treatment of Benign Prostatic Hyperplasia: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Medical Systems</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gain information on the safety, efficacy, and quality of
      life in subjects who have had the GreenLight XPS procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective chart review conducted at six centers in the United States and
      Canada. This review will evaluate the safety and efficacy of GreenLight XPS in subjects who
      received treatment on or after 01-Aug-2010.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Evaluate the proportion of patients who have mild or no BPH symptoms at 2-years post-procedure</measure>
    <time_frame>2-years post-procedure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the occurrence of adverse events related to the study treatment.</measure>
    <time_frame>Up to 4 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summarize characteristics of the study procedure and immediate outcomes.</measure>
    <time_frame>Participants will be followed from admission through discharge from the medical facility, an expected average of 2 days.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess changes in quality of life related to BPH symptoms.</measure>
    <time_frame>Baseline through five years post-procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess changes in objective measures of urologic function.</measure>
    <time_frame>From baseline through five years post-procedure.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize medical attention sought for treatment-related adverse events.</measure>
    <time_frame>Up to 90 days post-procedure.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the frequency of treatment-related urinary incontinence.</measure>
    <time_frame>Up to 12 months post-procedure.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the occurrence of surgical retreatment for BPH in GreenLight XPS patients.</measure>
    <time_frame>Procedure through five years post-procedure.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>GreenLight XPS Laser System</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GreenLight XPS Laser System</intervention_name>
    <arm_group_label>GreenLight XPS Laser System</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of males who have had the GreenLight XPS procedure with
        the MoXy fiber on or after 01-Aug-2010. The cohort will be selected from six pre-selected
        urology clinics in the US and one pre-selected urology clinic in Canada.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men who have had a GreenLight XPS procedure with a MoXy Fiber since 01-Aug-2010.

        Exclusion Criteria:

          -  Subject has had prior radiation.

          -  Subject has a diagnosis of neurogenic bladder confirmed by urodynamic studies (BOO,
             detrusor overactivity (DO), impaired detrusor contractor (IDC))

          -  Subject has a neurologic disorder that would impact bladder function (MS, Parkinson,
             Spinal Cord Injury) (note: Stroke patients not excluded)

          -  Subject has an artificial urinary sphincter
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmood A. Hai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliates Division, Comprehensive Urology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Olson</last_name>
    <phone>952-930-6000</phone>
    <email>laura.olson@ammd.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>El Camino Urology Medical Group, Inc.</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edward Karpman, M.D.</last_name>
      <phone>650-962-4663</phone>
    </contact>
    <investigator>
      <last_name>Edward Karpman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Urology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lewis Kriteman, M.D.</last_name>
      <phone>770-475-7550</phone>
    </contact>
    <investigator>
      <last_name>Lewis Kriteman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliates Division, Comprehensive Urology</name>
      <address>
        <city>Westland</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mahmood A. Hai, M.D.</last_name>
      <phone>734-595-1487</phone>
    </contact>
    <investigator>
      <last_name>Mahmood A. Hai, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Metro Urology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ricardo R. Gonzalez, M.D.</last_name>
      <phone>713-790-9779</phone>
    </contact>
    <investigator>
      <last_name>Ricardo R. Gonzalez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia, PLLC</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregg Eure, M.D.</last_name>
      <phone>757-452-3461</phone>
    </contact>
    <investigator>
      <last_name>Gregg Eure, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Montreal Hospital Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin Zorn, M.D.</last_name>
      <phone>514-861-0213</phone>
    </contact>
    <investigator>
      <last_name>Kevin Zorn, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>May 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
